Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management

Brookline Capital Management reissued their hold rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS - Free Report) in a research report released on Wednesday,Benzinga reports.

SYRS has been the topic of several other research reports. JMP Securities reissued a "market perform" rating on shares of Syros Pharmaceuticals in a research note on Wednesday. HC Wainwright reissued a "neutral" rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday. TD Cowen reaffirmed a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday. Piper Sandler reissued an "overweight" rating and set a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, StockNews.com downgraded shares of Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

SYRS traded down $2.37 on Wednesday, reaching $0.36. The stock had a trading volume of 37,518,992 shares, compared to its average volume of 457,067. The firm has a 50-day moving average of $2.04 and a 200-day moving average of $3.85. Syros Pharmaceuticals has a fifty-two week low of $0.35 and a fifty-two week high of $8.17. The company has a market capitalization of $9.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.59. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the business posted ($1.35) earnings per share. As a group, sell-side analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity at Syros Pharmaceuticals

In other news, CEO Conley Chee bought 50,000 shares of the stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 72,504 shares in the company, valued at approximately $109,481.04. This trade represents a 200.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Jason Haas acquired 45,344 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $1.68 per share, with a total value of $76,177.92. Following the acquisition, the chief financial officer now owns 124,552 shares in the company, valued at $209,247.36. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Conley Chee acquired 50,000 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were acquired at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the acquisition, the chief executive officer now owns 72,504 shares of the company's stock, valued at approximately $109,481.04. The trade was a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 130,707 shares of company stock valued at $206,491 over the last 90 days. Insiders own 12.26% of the company's stock.

Institutional Trading of Syros Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Opaleye Management Inc. grew its position in shares of Syros Pharmaceuticals by 119.1% in the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company's stock valued at $4,213,000 after purchasing an additional 428,175 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Syros Pharmaceuticals during the first quarter valued at approximately $2,166,000. Vanguard Group Inc. increased its holdings in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock worth $4,965,000 after acquiring an additional 163,234 shares during the period. Certuity LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $109,000. Finally, Acadian Asset Management LLC boosted its holdings in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company's stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Institutional investors own 91.47% of the company's stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.